BIOTECH ASSISTANT / FIELD NOTES

Vitamin E-derived lipid reduces inflammatory signals in experimental mRNA delivery

Academic source · ACS Nano

Source published: 2026-11-07 · Event / reporting date: 2026-11-07

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

Based on the publisher-deposited abstract, researchers modified an SM-102-derived ionizable lipid with vitamin E to create W3. Intravenous W3 LNP delivery reduced inflammatory cytokines and oxidative stress relative to SM-102 LNPs. An optimized spleen-directed formulation also showed improved antitumor activity. These experimental findings do not establish clinical safety or efficacy.

Why this paper is included

Analysis: Antioxidant lipid design may offer an additional delivery-safety optimization route; translation still requires reproducible characterization and dedicated toxicology.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP Formulation Development & Manufacturing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Asymchem WuXi AppTec / WuXi TIDES Porton Pharma Almac Pharmaron

Explore field companies →Explore literature →

Related updates

2026-11-06Nature

ANGPTL3 base-editing study reports sustained protein lowering in nonhuman primates

A Nature study delivered guide RNA and base-editor mRNA in GalNAc lipid nanoparticles to inactivate liver ANGPTL3. Nonhuman primates showed mean ANGPTL3 protein reductions exceeding 90%, with durability assessed through three years after one dose. Lipid reductions were observed in animal models. Human liver-cell testing assessed selected off-target sites; the paper does not report human clinical efficacy.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Ask AI ↗

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

Companies mentionedModerna ↗

mRNA / LNP Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗